Press Release: TILT Biotherapeutics : TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting...
Read full article »
TILT Biotherapeutics is a Finland-based clinical-stage biotechnology company that develops oncolytic immunotherapies for the treatment of cancer.
Read more